IL6 and COVID-19: Tocilizumab, a recombinant humanized monoclonal antibody that targets the soluble and membrane-bound IL-6 receptor to inhibit IL-6 signaling, is used for the treatment of various inflammatory diseases and more recently COVID-19 and MIS-C (41, 42).